Trials / Completed
CompletedNCT02181686
Iperia/Sentus QP Study
Iperia Family / Sentus QP Master Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 152 (actual)
- Sponsor
- Biotronik SE & Co. KG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to confirm the safety and efficacy of the new Sentus OTW QP LV lead and Iperia ICD family. The study focuses on the safety and efficacy of the QP device system.
Conditions
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2014-07-04
- Last updated
- 2015-07-15
Locations
24 sites across 11 countries: Austria, Denmark, Finland, Germany, Italy, Latvia, Netherlands, Singapore, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT02181686. Inclusion in this directory is not an endorsement.